All In Biotech

Drug Trial Radar · NCT07265466

to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions Between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban

A Phase 1 Clinical Trial to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions Between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban in Healthy Volunteers.

Last checked: Nov 19, 2026Latest source record: Dec 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

96

Planned (sponsor's estimate)

Start

Nov 17, 2025

Primary completion

Mar 30, 2026

Study completion Mar 30, 2026

Sponsor

Lead sponsor
Onconic Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Dec 4, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Factorial
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years, up to 64 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban

Conditions

  • Drug Drug Interaction (DDI)

Interventions

  • JP-1366 and clopidogrelDrug

    A randomized, open label, multiple-dosing, 6-sequence, 3-period, 3-treatment, crossover design

  • JP-1366 and aspirinDrug

    An open-label, multiple-dosing, fixed sequence, 3-period design

  • JP-1366 and atorvastatinDrug

    An open-label, multiple-dosing, fixed sequence, 3-period design Period 1: Atorvastatin

  • JP-1366 and apixabanDrug

    An open-label, multiple-dosing, fixed sequence, 3-period design

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. [Part 1] Change in P2Y12 Reaction Unit (PRU) from baseline on day 8Time frame: baseline on day 8
  2. [Part 2] Emax of arachidonic acid-induced platelet aggregationTime frame: up to 48 hours post-dose on Day 1
  3. [Part 2] AUEC0-24 of arachidonic acid-induced platelet aggregationTime frame: up to 48 hours post-dose on Day 1
  4. [Part 2] Cmax,ss of JP-1366Time frame: up to 24 hours post-dose on Day 5
  5. [Part 2] AUCτ,ss of JP-1366Time frame: up to 24 hours post-dose on Day 5
  6. [Part 2] Cmax of AspirinTime frame: up to 48 hours post-dose on Day 1
  7. [Part 2] AUClast of AspirinTime frame: up to 48 hours post-dose on Day 1
  8. [Part 3] Cmax,ss of JP-1366Time frame: up to 24 hours post-dose on Day 5
  9. [Part 3] AUCτ,ss of JP-1366Time frame: up to 24 hours post-dose on Day 5
  10. [Part 3] Cmax,ss of AtorvastatinTime frame: up to 24 hours post-dose on Day 5
  11. [Part 3] AUCτ,ss of AtorvastatinTime frame: up to 24 hours post-dose on Day 5
  12. [Part 4] Emax of Anti-Factor Xa activityTime frame: up to 48 hours post-dose on Day 5
  13. [Part 4] AUEC0-12 of Anti-Factor Xa activityTime frame: up to 48 hours post-dose on Day 5
  14. [Part 4] Cmax,ss of JP-1366Time frame: up to 24 hours post-dose on Day 5
  15. [Part 4] AUCτ,ss of JP-1366Time frame: up to 24 hours post-dose on Day 5
  16. [Part 4] Cmax,ss of ApixabanTime frame: up to 12 hours post-dose on Day 5
  17. [Part 4] AUCτ,ss of ApixabanTime frame: up to 12 hours post-dose on Day 5

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cha University Bundang Medical Center

    Seongnam-si, Gyeonggi-do, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.